Second, since PD-1+CD8+ TILs are rich in tumour-specific cells, their TCRs can be obtained by single-cell sequencing and bioinformatics analysis, and new personalised TCR weapons may thus be obtained. The gene discussed is CD8A; the disease is neoplasm.